{"hands_on_practices": [{"introduction": "The accuracy of any endpoint titer determination is fundamentally rooted in the precision of the initial serial dilution. This exercise goes beyond theoretical dilution factors to address the practical realities of the laboratory bench. By considering constraints such as minimum pipetting volumes, required dead volumes, and efficient use of precious sample and reagents, you will derive an optimal dilution scheme from first principles, a critical skill for ensuring experimental reproducibility and validity.", "problem": "A laboratory performing Indirect Immunofluorescence Microscopy (IIF) to determine endpoint titers prepares a two-fold serial dilution series starting at $1:10$ and proceeding through $1:1280$ by successive $1:2$ steps. The workflow uses a constant transfer volume per step: the next dilution is generated by transferring a fixed volume $v$ of the current dilution into an equal volume $v$ of diluent (phosphate-buffered saline), producing a total of $2v$ in the next tube. The first tube ($1:10$) is prepared by mixing neat serum and diluent to achieve a total volume $V_{1}$ at a $1:10$ ratio of serum to total.\n\nThe following constraints apply:\n- Each dilution tube must provide enough volume to plate duplicate wells, each requiring $25$ µL, for a total of $50$ µL withdrawn from each tube for slide application.\n- Each tube must retain a dead volume of $D = 10$ µL after all withdrawals to avoid aspiration artifacts and ensure pipetting accuracy.\n- The constant transfer volume $v$ is identical for each $1:2$ step from $1:10$ through $1:1280$.\n- The minimum pipettable volume for any transfer is $10$ µL; the maximum tube capacity is $1000$ µL.\n- The available starting neat serum volume is $S = 200$ µL.\n- Assume ideal mixing and no evaporative or adsorption losses.\n\nStarting from core definitions of dilution and mass conservation, derive the minimal constant transfer volume $v$ that satisfies all constraints across the entire series and, under that minimal-volume scheme, compute the minimal total diluent volume required to complete the full series from $1:10$ to $1:1280$. Express your final answer as a single real number in µL. Round your answer to four significant figures.", "solution": "The serial dilution scheme is governed by the definition of dilution and conservation of mass. A dilution of $1:N$ means that the solute (serum) occupies a fraction $1/N$ of the total volume. For a $1:2$ step produced by mixing a volume $v$ of the current solution with a volume $v$ of diluent, the total volume in the new tube is $2v$, and the concentration is halved relative to the source tube by construction.\n\nWe label the tubes by dilution factors $D_{k}$, where $D_{1} = 10$ for the $1:10$ tube and $D_{k} = 10 \\cdot 2^{k-1}$ for $k = 1,2,\\dots,8$, with $D_{8} = 1280$. The $1:10$ tube is prepared by mixing neat serum volume $s_{1}$ and diluent volume $d_{1}$ to yield total volume $V_{1} = s_{1} + d_{1}$ with $s_{1}/V_{1} = 1/10$, hence\n$$\ns_{1} = \\frac{V_{1}}{10}, \\quad d_{1} = \\frac{9V_{1}}{10}.\n$$\n\nFor each subsequent $1:2$ step, we use a constant transfer volume $v$ of the prior tube into $v$ of diluent to produce the next tube, yielding exactly $2v$ volume in that tube.\n\nThe constraints dictate the minimal volumes required in each tube:\n- From every tube, $50$ µL must be withdrawn for plating (duplicates at $25$ µL each).\n- After all withdrawals from a tube, a dead volume of $D = 10$ µL must remain.\n- For all tubes except the last ($1:1280$), an additional volume $v$ must be available to transfer to the next tube.\n\nTherefore, for any intermediate tube (all except the last), the total available volume must satisfy\n$$\n2v \\geq v + 50 + D,\n$$\nwhich simplifies to\n$$\nv \\geq 50 + D.\n$$\nFor the last tube, no further transfer is needed, so the condition is\n$$\n2v \\geq 50 + D \\quad \\Rightarrow \\quad v \\geq \\frac{50 + D}{2}.\n$$\nThe tighter condition is $v \\geq 50 + D$.\n\nWe also have the minimum pipettable volume constraint $v \\geq 10$ µL; combining constraints gives\n$$\nv \\geq \\max\\{10,\\, 50 + D\\}.\n$$\nWith $D = 10$ µL, this yields\n$$\nv \\geq \\max\\{10,\\, 60\\} = 60 \\text{ µL}.\n$$\nThus, the minimal constant transfer volume satisfying all constraints is\n$$\nv = 60 \\text{ µL}.\n$$\n\nNext, we determine the minimal $V_{1}$ needed in the $1:10$ tube. This tube must provide $v$ for transfer to $1:20$, plus $50$ µL for plating, plus $D$ µL dead volume. Hence,\n$$\nV_{1} = v + 50 + D = 60 + 50 + 10 = 120 \\text{ µL}.\n$$\nThe corresponding neat serum used to prepare the $1:10$ tube is\n$$\ns_{1} = \\frac{V_{1}}{10} = \\frac{120}{10} = 12 \\text{ µL},\n$$\nwhich is within the minimum pipettable volume constraint and below the available $S = 200$ µL, so the starting sample is not limiting.\n\nWe now compute the total diluent volume required across the full series. This comprises:\n1. The initial diluent to prepare $1:10$:\n$$\nd_{1} = \\frac{9V_{1}}{10} = \\frac{9 \\cdot 120}{10} = 108 \\text{ µL}.\n$$\n2. The diluent added at each $1:2$ step from $1:20$ through $1:1280$. There are $7$ such steps (from tube $2$ to tube $8$), each requiring a diluent volume $v$:\n$$\nV_{\\text{diluent, steps}} = 7v = 7 \\cdot 60 = 420 \\text{ µL}.\n$$\n\nTherefore, the total minimal diluent volume required is\n$$\nV_{\\text{diluent, total}} = d_{1} + V_{\\text{diluent, steps}} = 108 + 420 = 528 \\text{ µL}.\n$$\n\nAll tube volumes under this scheme are at most $2v = 120$ µL, which complies with the $1000$ µL tube capacity. The minimum pipettable volume constraint is satisfied for all transfers ($v = 60$ µL and $s_{1} = 12$ µL both exceed $10$ µL). The duplicate plating and dead volume requirements are met by construction.\n\nRounded to four significant figures, the total diluent volume is $528.0$ µL.", "answer": "$$\\boxed{528.0}$$", "id": "5126419"}, {"introduction": "Distinguishing between different antinuclear antibody (ANA) patterns is a cornerstone of autoimmune disease diagnostics. This practice moves beyond qualitative visual inspection to the realm of quantitative, rule-based classification. You will use your knowledge of cell biology, specifically the behavior of chromosomes and nuclear structures, to construct a decision algorithm that can reliably differentiate clinically important patterns like the centromere and discrete speckled patterns based on objective image features [@problem_id:5126465].", "problem": "A clinical laboratory uses Indirect Immunofluorescence (IIF) on human epithelial type 2 (HEp-2) cells to characterize Anti-Nuclear Antibody (ANA) patterns and determine endpoint titers. In IIF, patient immunoglobulin G (IgG) binds cognate nuclear antigens, and a fluorophore-conjugated secondary antibody reports the spatial distribution of the bound IgG. The fundamental bases for interpretation are: antigen–antibody binding specificity, the conservation of antigen subcellular topology across dilutions where the Signal-to-Noise Ratio (SNR) is above threshold, and the definition of titer as the highest serum dilution at which the specific pattern remains detectable above background. Patterns arise from the intrinsic cellular distribution of target antigens: centromere/kinetochore proteins occupy discrete foci at chromosomal centromeres, while antigens producing discrete speckled patterns localize to nuclear euchromatin or other nuclear structures not constrained to kinetochore positions.\n\nA computational pipeline segments nuclei and extracts, for each dilution, quantitative features from a set of interphase nuclei and any observable metaphase cells:\n- Mean spot count per interphase nucleus, denoted $\\mu$.\n- Coefficient of Variation (CV) of spot counts across interphase nuclei, denoted $\\mathrm{CV} = \\sigma / \\mu$, where $\\sigma$ is the standard deviation.\n- Median spot diameter, denoted $s$ (in $\\mu\\mathrm{m}$), estimated from diffraction-limited spot fits.\n- A binary metaphase alignment indicator $M$, where $M = 1$ if metaphase cells (when present) show discrete dots aligned on the metaphase plate; otherwise $M = 0$.\n- Presence of nucleolar exclusion, $E$, where $E = 1$ if spots are absent from nucleoli; otherwise $E = 0$.\n\nImages are acquired at serial dilutions $1{:}80$, $1{:}160$, and $1{:}320$; the endpoint titer $T_e$ is determined by an SNR threshold $\\tau$ such that the pattern is called positive at dilution $1{:}d$ if $\\mathrm{SNR}(1{:}d) \\ge \\tau$ and negative otherwise. Assume that as $d$ increases, overall intensity decreases approximately proportionally to antibody occupancy, but the topology (number, size, and subnuclear positions of spots) of a true pattern does not change across dilutions where $\\mathrm{SNR} \\ge \\tau$.\n\nConstruct decision rules that distinguish the centromere (kinetochore) pattern from discrete speckled patterns using the measured features and the above base assumptions. Which of the following single-rule classifiers is most scientifically sound and operationally specific for classifying a pattern as centromere versus discrete speckled across the stated dilutions, while adhering to the requirement that classification must be based on topology rather than absolute intensity?\n\nA. Classify as centromere if simultaneously: $\\mu \\in [40,60]$ at all dilutions with $\\mathrm{SNR} \\ge \\tau$; $\\mathrm{CV} \\le 0.20$ across interphase nuclei; $s \\in [0.3,0.7]\\,\\mu\\mathrm{m}$; $M = 1$ when metaphase is present; and $E = 1$. Otherwise, classify as discrete speckled. Titer magnitude is used only to ensure that the topology is assessed where $\\mathrm{SNR} \\ge \\tau$, not as a direct classifier.\n\nB. Classify as centromere if the endpoint titer $T_e \\ge 1{:}320$ and the mean spot count $\\mu \\ge 30$ at $1{:}80$; otherwise classify as discrete speckled. Spatial distribution features are not required.\n\nC. Classify as centromere if $\\mu \\le 30$ at any positive dilution and $s \\ge 0.8\\,\\mu\\mathrm{m}$, regardless of metaphase behavior or nucleolar exclusion; otherwise classify as discrete speckled.\n\nD. Classify as centromere if $\\mu \\in [40,60]$ at $1{:}80$ only, allowing $\\mathrm{CV} \\ge 0.50$ and ignoring metaphase alignment and nucleolar exclusion; otherwise classify as discrete speckled.\n\nE. Classify as centromere if the spot density (spot count divided by nuclear area) decreases proportionally with dilution such that density at $1{:}320$ is $\\approx 25\\%$ of that at $1{:}80$; otherwise classify as discrete speckled. Ignore metaphase alignment and nucleolar exclusion.\n\nSelect the single best option.", "solution": "The user has requested a critical evaluation of a problem concerning the classification of Anti-Nuclear Antibody (ANA) patterns in Indirect Immunofluorescence (IIF) microscopy. The task is to validate the problem statement and, if valid, derive the most scientifically sound and specific single-rule classifier for distinguishing a centromere pattern from a discrete speckled pattern among the given options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n- **Assay**: Indirect Immunofluorescence (IIF) on human epithelial type $2$ (HEp-$2$) cells.\n- **Objective**: Characterize ANA patterns and determine endpoint titers.\n- **Mechanism**: Patient immunoglobulin G (IgG) binds to nuclear antigens; a fluorophore-conjugated secondary antibody detects the bound IgG.\n- **Fundamental Principles**:\n    1.  Antigen–antibody binding specificity.\n    2.  Conservation of antigen subcellular topology across dilutions where Signal-to-Noise Ratio (SNR) is above a threshold $\\tau$.\n    3.  Titer is the highest serum dilution where the specific pattern is detectable above background.\n- **Pattern Definitions**:\n    - **Centromere/Kinetochore**: Discrete foci at chromosomal centromeres.\n    - **Discrete Speckled**: Antigens in nuclear euchromatin or other nuclear structures not limited to kinetochore positions.\n- **Quantitative Features**:\n    - $\\mu$: Mean spot count per interphase nucleus.\n    - $\\mathrm{CV}$: Coefficient of Variation of spot counts ($\\sigma / \\mu$).\n    - $s$: Median spot diameter in $\\mu\\mathrm{m}$.\n    - $M$: Binary metaphase alignment indicator ($M=1$ if spots align on the metaphase plate; $M=0$ otherwise).\n    - $E$: Binary nucleolar exclusion indicator ($E=1$ if spots are absent from nucleoli; $E=0$ otherwise).\n- **Experimental Conditions**:\n    - Serial dilutions: $1{:}80$, $1{:}160$, $1{:}320$.\n    - Endpoint titer $T_e$ is set by SNR threshold $\\tau$: positive at dilution $1{:}d$ if $\\mathrm{SNR}(1{:}d) \\ge \\tau$.\n- **Core Assumption**: As dilution factor $d$ increases, intensity decreases, but topology (number, size, position of spots) of a true pattern is conserved for all dilutions where $\\mathrm{SNR} \\ge \\tau$.\n- **Task Constraint**: Classification must be based on topology, not absolute intensity.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded**: The problem is scientifically sound. The description of IIF, HEp-2 cells as a substrate, ANA patterns, and the definition of a titer are standard in clinical immunology and cell biology. The distinction between centromere and speckled patterns based on antigen location is accurate. Human somatic cells have $46$ chromosomes. In the G1 phase of the cell cycle, this corresponds to $46$ centromeres. Following DNA replication (in G2/M phase), each of the $46$ chromosomes has two sister chromatids, each with a kinetochore, leading to up to $92$ potential spots. Therefore, an expected mean spot count $\\mu$ for a centromere pattern in an asynchronous cell population would be centered around $46$, and the number of spots per cell would be tightly regulated, leading to a low coefficient of variation ($\\mathrm{CV}$). The alignment of centromeres on the metaphase plate during mitosis ($M=1$) is a classic and definitive feature. Nucleolar exclusion ($E=1$) is also biologically correct as chromosomes reside in the nucleoplasm, separate from nucleoli. All premises are factually correct and grounded in established cell biology.\n\n2.  **Well-Posed**: The problem is well-posed. It asks for the selection of the \"most scientifically sound and operationally specific\" classifier from a set of options, based on a clearly defined set of principles and features. The goal is clear, and the provided information is sufficient to evaluate the options.\n\n3.  **Objective**: The problem is stated objectively using precise, technical language common to the field. It is free of subjective or ambiguous terminology.\n\n4.  **Flaw Checklist**: The problem does not exhibit any of the listed flaws. It is not scientifically unsound, incomplete, contradictory, unrealistic, or ill-posed. The parameters and assumptions provided are standard for this type of analysis.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. The premises are scientifically and logically sound, self-contained, and sufficient for proceeding to a solution.\n\n### Derivation of a Solution\n\nThe goal is to formulate a classifier that specifically identifies the centromere pattern based on its unique topological characteristics, independent of signal intensity (and thus, titer magnitude).\n\n**First Principles of the Centromere Pattern:**\n\n1.  **Spot Count ($\\mu$)**: The number of centromeres is determined by the number of chromosomes. In a non-aneuploid human diploid cell, this is $46$. In G1 phase, we expect $46$ spots. In G2/M, we expect up to $92$. An asynchronous population's mean count should therefore be in this range, typically closer to the G1 value, e.g., $\\mu \\approx 46-50$. A rule with a range like $[40, 60]$ is thus biologically justified.\n\n2.  **Spot Count Variation ($\\mathrm{CV}$)**: Because the number of centromeres is strictly tied to chromosome number, the variation in this count from cell to cell is low compared to other nuclear speckles, which are not as stoichiometrically controlled. Therefore, a low $\\mathrm{CV}$ (e.g., $\\mathrm{CV} \\le 0.20$) is a strong identifying feature.\n\n3.  **Topological Conservation**: The problem states that topology is conserved across dilutions where $\\mathrm{SNR} \\ge \\tau$. This implies that the characteristic features, such as $\\mu$ and $\\mathrm{CV}$, must remain stable across all dilutions deemed positive. A robust classifier must verify this stability.\n\n4.  **Metaphase Alignment ($M$)**: During mitosis, chromosomes align at the metaphase plate. The centromeres are integral to this process. Consequently, a key, highly specific feature of the centromere pattern is the alignment of the fluorescent spots along the metaphase plate in dividing cells. A rule must require $M=1$ if metaphase cells are observed.\n\n5.  **Nucleolar Exclusion ($E$)**: Centromeres are part of the chromosomal structure, located in the nucleoplasm. They are not found within the nucleoli. Therefore, spots should be absent from nucleoli, meaning $E=1$.\n\n6.  **Spot Size ($s$)**: Kinetochores are complex protein structures but are physically small (sub-micron). In light microscopy, they appear as diffraction-limited spots. The apparent size is dictated by the microscope's point spread function, typically in the range of $0.2-0.5\\,\\mu\\mathrm{m}$. A range like $[0.3, 0.7]\\,\\mu\\mathrm{m}$ is a reasonable expectation.\n\n**Optimal Classifier Construction**:\nAn ideal classifier would integrate all these features to maximize specificity. It would require:\n- A stable mean spot count $\\mu$ in the chromosomally-defined range (e.g., $[40, 60]$) across all positive dilutions.\n- A low spot count variation $\\mathrm{CV}$ (e.g., $\\le 0.20$).\n- A spot size $s$ consistent with diffraction-limited objects.\n- Positive metaphase alignment $M=1$.\n- Positive nucleolar exclusion $E=1$.\n- It must explicitly use titer only to define the range of dilutions for analysis, not as a classification feature itself, per the problem's constraint.\n\n### Option-by-Option Analysis\n\n**A. Classify as centromere if simultaneously: $\\mu \\in [40,60]$ at all dilutions with $\\mathrm{SNR} \\ge \\tau$; $\\mathrm{CV} \\le 0.20$ across interphase nuclei; $s \\in [0.3,0.7]\\,\\mu\\mathrm{m}$; $M = 1$ when metaphase is present; and $E = 1$. Otherwise, classify as discrete speckled. Titer magnitude is used only to ensure that the topology is assessed where $\\mathrm{SNR} \\ge \\tau$, not as a direct classifier.**\n\nThis option perfectly matches the derived optimal classifier. It correctly specifies the biologically-expected range for $\\mu$, the low $\\mathrm{CV}$, the conservation of these features across all positive dilutions, the appropriate spot size $s$, and the critical confirmatory features of metaphase alignment ($M=1$) and nucleolar exclusion ($E=1$). It also correctly states the role of titer, adhering to the problem's constraints. This classifier is highly specific and scientifically sound.\n**Verdict: Correct**\n\n**B. Classify as centromere if the endpoint titer $T_e \\ge 1{:}320$ and the mean spot count $\\mu \\ge 30$ at $1{:}80$; otherwise classify as discrete speckled. Spatial distribution features are not required.**\n\nThis option is fundamentally flawed. It violates the primary constraint that \"classification must be based on topology rather than absolute intensity.\" Endpoint titer ($T_e$) is a measure of antibody concentration/avidity, which relates to intensity. Using a high titer ($T_e \\ge 1{:}320$) as a classification criterion is incorrect. Furthermore, it ignores almost all specific topological information (CV, M, E) and sets a loose, non-specific threshold for spot count ($\\mu \\ge 30$). Many high-titer discrete speckled patterns could meet these criteria.\n**Verdict: Incorrect**\n\n**C. Classify as centromere if $\\mu \\le 30$ at any positive dilution and $s \\ge 0.8\\,\\mu\\mathrm{m}$, regardless of metaphase behavior or nucleolar exclusion; otherwise classify as discrete speckled.**\n\nThis option uses biologically incorrect parameters. The spot count for a centromere pattern should be around $46$, not $\\le 30$. A spot size of $s \\ge 0.8\\,\\mu\\mathrm{m}$ is too large for a single kinetochore and is not characteristic of the fine, discrete spots of a centromere pattern. Ignoring metaphase alignment ($M$) and nucleolar exclusion ($E$) discards the most specific indicators.\n**Verdict: Incorrect**\n\n**D. Classify as centromere if $\\mu \\in [40,60]$ at $1{:}80$ only, allowing $\\mathrm{CV} \\ge 0.50$ and ignoring metaphase alignment and nucleolar exclusion; otherwise classify as discrete speckled.**\n\nThis rule is weak and non-specific. By checking the condition at \"$1{:}80$ only\", it fails to enforce the principle of topological conservation across dilutions. By \"allowing $\\mathrm{CV} \\ge 0.50$\", it permits high variability, which is characteristic of non-centromere speckled patterns, not the tightly regulated centromere count. Ignoring $M$ and $E$ removes crucial confirmatory evidence. This classifier would have high false-positive rates.\n**Verdict: Incorrect**\n\n**E. Classify as centromere if the spot density (spot count divided by nuclear area) decreases proportionally with dilution such that density at $1{:}320$ is $\\approx 25\\%$ of that at $1{:}80$; otherwise classify as discrete speckled. Ignore metaphase alignment and nucleolar exclusion.**\n\nThis option is based on a premise that directly contradicts the problem's core assumption. The problem states that the topology, including the **number of spots**, is conserved across dilutions with $\\mathrm{SNR} \\ge \\tau$. If the spot count is conserved, and nuclear area is constant for a given cell, the spot density must also be conserved. This rule describes a scenario where the number of detectable spots decreases with dilution (a $4$-fold dilution from $1{:}80$ to $1{:}320$ leads to a $4$-fold decrease in density), which reflects the signal fading below the detection threshold, not a stable topological feature of the pattern itself. It misinterprets signal fall-off as a defining characteristic.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "5126465"}, {"introduction": "The conventional endpoint titer, while a clinical workhorse, is an ordinal metric that can lack statistical robustness. This exercise introduces a modern, quantitative approach to titer analysis by framing the problem in a probabilistic context. You will apply logistic regression to model the probability of a positive result as a function of dilution, allowing you to calculate a more continuous and objective metric like the dilution corresponding to a $0.5$ probability of positivity ($d_{0.5}$), a powerful concept in quantitative immunodiagnostics [@problem_id:5126471].", "problem": "A laboratory performing Indirect Immunofluorescence microscopy (IIF) on Human Epithelial type 2 (HEp-2) cells seeks to formalize a probabilistic alternative to the conventional antibody titer (highest dilution with a positive fluorescence readout). For a given serum, the laboratory performs replicate IIF reads at two dilution denominators, $d_1$ and $d_2$, each read being independently classified as positive or negative according to a validated fluorescence threshold. Let $y_i$ denote the number of positive reads out of $n_i$ replicates at dilution denominator $d_i$, with $i \\in \\{1,2\\}$, and let the predictor be the natural logarithm of the dilution denominator, $x_i = \\ln(d_i)$. Assume the binary positivity at each replicate follows independent Bernoulli trials with probability $p(x)$ that is linked to $x$ using the canonical logistic regression definition, namely the log-odds (logit) of positivity is linear in $x$.\n\nStarting from the definitions of Bernoulli and binomial likelihood and the logistic link, build the maximum likelihood estimate for the logistic regression with one predictor and two parameter coefficients, and derive the dilution denominator $d_{0.5}$ at which the model-implied probability of positivity is $0.5$. Use the following scientifically realistic dataset:\n- Dilution denominators: $d_1 = 80$ and $d_2 = 320$, so $x_1 = \\ln(80)$ and $x_2 = \\ln(320)$.\n- Replicate counts: $n_1 = 8$ and $n_2 = 8$.\n- Positives observed: $y_1 = 5$ at $d_1$ and $y_2 = 2$ at $d_2$.\n\nExpress your final answer for the dilution denominator at $0.5$ probability, $d_{0.5}$, as a single closed-form analytic expression in terms of elementary functions. Do not provide a numerical approximation; no rounding is required. The answer must be a single expression and must not include any units.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in standard immunodiagnostic and statistical principles, is well-posed with sufficient and consistent data, and is formulated objectively. We may therefore proceed with a formal solution.\n\nThe problem requires the derivation of the dilution denominator $d_{0.5}$ at which the probability of a positive test is $0.5$, based on a logistic regression model fitted to data from an Indirect Immunofluorescence (IIF) assay.\n\nThe logistic regression model relates the probability of a positive outcome, $p(x)$, to a predictor variable $x$ via the logit link function. The predictor is the natural logarithm of the dilution denominator, $x = \\ln(d)$. The model is defined as:\n$$\n\\text{logit}(p(x)) = \\ln\\left(\\frac{p(x)}{1-p(x)}\\right) = \\beta_0 + \\beta_1 x\n$$\nSolving for $p(x)$ gives the logistic function:\n$$\np(x) = \\frac{\\exp(\\beta_0 + \\beta_1 x)}{1 + \\exp(\\beta_0 + \\beta_1 x)}\n$$\nThe data consists of two groups, indexed by $i \\in \\{1, 2\\}$. For each group $i$, we have $n_i$ replicate reads at dilution denominator $d_i$, with $x_i = \\ln(d_i)$. The number of positive reads is $y_i$. The observation $y_i$ is a realization of a random variable $Y_i$ that follows a binomial distribution, $Y_i \\sim \\text{Binomial}(n_i, p_i)$, where $p_i = p(x_i)$.\n\nThe likelihood function $L(\\beta_0, \\beta_1)$ is the product of the probabilities of observing $y_1$ and $y_2$, assuming independence between the two groups:\n$$\nL(\\beta_0, \\beta_1) = \\binom{n_1}{y_1} p_1^{y_1} (1-p_1)^{n_1-y_1} \\cdot \\binom{n_2}{y_2} p_2^{y_2} (1-p_2)^{n_2-y_2}\n$$\nTo find the maximum likelihood estimates (MLEs) for $\\beta_0$ and $\\beta_1$, we maximize the log-likelihood function, $\\ell(\\beta_0, \\beta_1) = \\ln(L(\\beta_0, \\beta_1))$.\n$$\n\\ell(\\beta_0, \\beta_1) = \\text{const} + y_1 \\ln(p_1) + (n_1-y_1) \\ln(1-p_1) + y_2 \\ln(p_2) + (n_2-y_2) \\ln(1-p_2)\n$$\nUsing the relations $\\ln(p_i) = \\beta_0 + \\beta_1 x_i - \\ln(1 + \\exp(\\beta_0 + \\beta_1 x_i))$ and $\\ln(1-p_i) = -\\ln(1 + \\exp(\\beta_0 + \\beta_1 x_i))$, the log-likelihood can be written as:\n$$\n\\ell(\\beta_0, \\beta_1) = \\text{const} + \\sum_{i=1}^{2} \\left[ y_i (\\beta_0 + \\beta_1 x_i) - n_i \\ln(1+\\exp(\\beta_0 + \\beta_1 x_i)) \\right]\n$$\nThe MLEs $(\\hat{\\beta}_0, \\hat{\\beta}_1)$ are found by setting the partial derivatives of $\\ell$ with respect to $\\beta_0$ and $\\beta_1$ to zero.\n$$\n\\frac{\\partial \\ell}{\\partial \\beta_0} = \\sum_{i=1}^{2} \\left( y_i - n_i \\frac{\\exp(\\beta_0 + \\beta_1 x_i)}{1+\\exp(\\beta_0 + \\beta_1 x_i)} \\right) = \\sum_{i=1}^{2} (y_i - n_i p_i) = 0\n$$\n$$\n\\frac{\\partial \\ell}{\\partial \\beta_1} = \\sum_{i=1}^{2} \\left( y_i x_i - n_i x_i \\frac{\\exp(\\beta_0 + \\beta_1 x_i)}{1+\\exp(\\beta_0 + \\beta_1 x_i)} \\right) = \\sum_{i=1}^{2} x_i (y_i - n_i p_i) = 0\n$$\nIn this specific problem, we have two parameters ($\\beta_0, \\beta_1$) and two data groups (at $x_1, x_2$). This constitutes a \"saturated\" model. For a saturated binomial logistic regression, the likelihood is maximized when the fitted probabilities $\\hat{p}_i$ are equal to the observed sample proportions $y_i/n_i$. Thus, the score equations are satisfied by setting $\\hat{p}_i = y_i/n_i$ for $i \\in \\{1, 2\\}$.\n\nThis provides a system of two linear equations for $\\beta_0$ and $\\beta_1$:\n$$\n\\ln\\left(\\frac{y_1/n_1}{1 - y_1/n_1}\\right) = \\hat{\\beta}_0 + \\hat{\\beta}_1 x_1\n$$\n$$\n\\ln\\left(\\frac{y_2/n_2}{1 - y_2/n_2}\\right) = \\hat{\\beta}_0 + \\hat{\\beta}_1 x_2\n$$\nLet $L_i = \\ln\\left(\\frac{y_i/n_i}{1 - y_i/n_i}\\right) = \\ln\\left(\\frac{y_i}{n_i - y_i}\\right)$ be the empirical log-odds. The system is $L_1 = \\hat{\\beta}_0 + \\hat{\\beta}_1 x_1$ and $L_2 = \\hat{\\beta}_0 + \\hat{\\beta}_1 x_2$.\n\nWe are asked to find the dilution denominator $d_{0.5}$ where the probability of positivity is $0.5$. Let $x_{0.5} = \\ln(d_{0.5})$. At this point, $p(x_{0.5}) = 0.5$. The logit is:\n$$\n\\ln\\left(\\frac{0.5}{1-0.5}\\right) = \\ln(1) = 0\n$$\nSo, we must find $x_{0.5}$ such that $\\hat{\\beta}_0 + \\hat{\\beta}_1 x_{0.5} = 0$. This implies $x_{0.5} = -\\frac{\\hat{\\beta}_0}{\\hat{\\beta}_1}$.\n\nSolving the linear system for $\\hat{\\beta}_0$ and $\\hat{\\beta}_1$:\nSubtracting the first equation from the second gives $\\hat{\\beta}_1 = \\frac{L_2 - L_1}{x_2 - x_1}$.\nSubstituting $\\hat{\\beta}_1$ back into the first equation gives $\\hat{\\beta}_0 = L_1 - x_1 \\frac{L_2 - L_1}{x_2 - x_1} = \\frac{L_1(x_2 - x_1) - x_1(L_2 - L_1)}{x_2 - x_1} = \\frac{x_2 L_1 - x_1 L_2}{x_2 - x_1}$.\n\nNow we can compute $x_{0.5}$:\n$$\nx_{0.5} = -\\frac{\\hat{\\beta}_0}{\\hat{\\beta}_1} = - \\frac{(x_2 L_1 - x_1 L_2)/(x_2 - x_1)}{(L_2 - L_1)/(x_2 - x_1)} = - \\frac{x_2 L_1 - x_1 L_2}{L_2 - L_1} = \\frac{x_2 L_1 - x_1 L_2}{L_1 - L_2}\n$$\nThis is the linear interpolation formula for the point where the line connecting $(x_1, L_1)$ and $(x_2, L_2)$ crosses the horizontal axis.\n\nThe desired quantity is $d_{0.5} = \\exp(x_{0.5})$.\n$$\nd_{0.5} = \\exp\\left(\\frac{x_2 L_1 - x_1 L_2}{L_1 - L_2}\\right)\n$$\nWe substitute the given data:\n- $d_1 = 80 \\implies x_1 = \\ln(80)$\n- $d_2 = 320 \\implies x_2 = \\ln(320)$\n- $n_1 = 8, y_1 = 5 \\implies L_1 = \\ln\\left(\\frac{5}{8-5}\\right) = \\ln\\left(\\frac{5}{3}\\right)$\n- $n_2 = 8, y_2 = 2 \\implies L_2 = \\ln\\left(\\frac{2}{8-2}\\right) = \\ln\\left(\\frac{2}{6}\\right) = \\ln\\left(\\frac{1}{3}\\right)$\n\nFirst, calculate the denominator of the exponent, $L_1 - L_2$:\n$$\nL_1 - L_2 = \\ln\\left(\\frac{5}{3}\\right) - \\ln\\left(\\frac{1}{3}\\right) = \\ln\\left(\\frac{5/3}{1/3}\\right) = \\ln(5)\n$$\nNext, calculate the numerator of the exponent, $x_2 L_1 - x_1 L_2$:\n$$\nx_2 L_1 - x_1 L_2 = \\ln(320) \\ln\\left(\\frac{5}{3}\\right) - \\ln(80) \\ln\\left(\\frac{1}{3}\\right)\n$$\nUsing logarithm properties $\\ln(a/b) = \\ln(a) - \\ln(b)$ and $\\ln(1/b) = -\\ln(b)$:\n$$\n= \\ln(320)(\\ln(5) - \\ln(3)) - \\ln(80)(-\\ln(3))\n= \\ln(320)\\ln(5) - \\ln(320)\\ln(3) + \\ln(80)\\ln(3)\n= \\ln(320)\\ln(5) + (\\ln(80) - \\ln(320))\\ln(3)\n$$\nSince $\\ln(80) - \\ln(320) = \\ln(80/320) = \\ln(1/4) = -\\ln(4)$:\n$$\n= \\ln(320)\\ln(5) - \\ln(4)\\ln(3)\n$$\nNow, assemble the expression for $x_{0.5}$:\n$$\nx_{0.5} = \\frac{\\ln(320)\\ln(5) - \\ln(4)\\ln(3)}{\\ln(5)} = \\ln(320) - \\frac{\\ln(4)\\ln(3)}{\\ln(5)}\n$$\nFinally, we find $d_{0.5}$ by exponentiating $x_{0.5}$:\n$$\nd_{0.5} = \\exp(x_{0.5}) = \\exp\\left(\\ln(320) - \\frac{\\ln(4)\\ln(3)}{\\ln(5)}\\right)\n$$\n$$\nd_{0.5} = \\exp(\\ln(320)) \\cdot \\exp\\left(-\\frac{\\ln(4)\\ln(3)}{\\ln(5)}\\right)\n$$\n$$\nd_{0.5} = 320 \\exp\\left(-\\frac{\\ln(4)\\ln(3)}{\\ln(5)}\\right)\n$$\nThis is the final closed-form analytic expression for the dilution denominator $d_{0.5}$.", "answer": "$$\n\\boxed{320 \\exp\\left(-\\frac{\\ln(4)\\ln(3)}{\\ln(5)}\\right)}\n$$", "id": "5126471"}]}